Eurobio Scientific has launched the new EBX 048, Eurobioplex SARS-CoV-2 Fast Screening and VOC Typing (SVT) real-time polymerase chain reaction (RT-PCR) test.
The assay has been specifically developed for routine screening of Covid-19, as well as detection of the current variants of the SARS-CoV-2 virus, including the Omicron BA.x, BA.2 and Delta variants.
The Eurobioplex SARS-CoV-2 Fast-SVT test detects the K417N mutation present on the Omicron variant BA.x and the L452R mutation present on the Delta variant.
It also detects the V213G mutation on the Omicron variant BA.2.
The company stated that the V213G mutation presence enables the differentiation of the BA.2 sublineage from the other sublineages of the Omicron variant.
Eurobio’s new RT-PCR test requires only one reaction and provides results in 45 minutes.
The research and development (R&D) team of Eurobio Scientific has designed and developed the new test in-house at its facility located in Les Ulis, France.
Eurobio Scientific said in a statement: “The Eurobioplex SARS-CoV-2 Fast-SVT test is available in several versions, allowing 50, 100 or 200 determinations to be performed simultaneously.”
Furthermore, the assay is immediately available in its research use only (RUO) version to private laboratories and hospitals in France and worldwide.
Last December, the company obtained the CE mark for its EBX 047, Eurobioplex SARS-CoV-2 Fast Screening and Variants Detection (SVD) test.
This test has been specifically developed to detect Covid-19 and its Omicron and Delta variants.
It targets the K417N mutation present on the Omicron and Beta variants, L452R mutation on the Delta variant, and E484K mutation present on the Beta and Gamma variants.